Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Data Disclosure: PhRMA Principles Rely On Review Boards To Screen Research Proposals

This article was originally published in The Pink Sheet Daily

Executive Summary

PhRMA and EFPIA issue joint principles that urge firms to release the synopses of clinical study reports; PhRMA objects to FDA’s proposal to release masked, de-identified data on the grounds of patient privacy, competitive secrecy.

You may also be interested in...



US FDA Threatens Fines For ClinicalTrials.gov Noncompliance

Draft guidance states that "responsible parties" could be fined $10,000 for not submitting trial information to the federal data repository as required by law.

ClinicalTrials.gov Still Lacks Many Study Results, JAMA Finds; Do Transparency Efforts Need A Boost?

Industry data transparency initiatives are well-established now, but JAMA study suggests holes in efforts to publicly release clinical trial results.

FDA’s Robyn Bent On The Evolution of Patient-Focused Drug Development

The director of the agency’s patient focused drug development program talks to the Pink Sheet about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel